source
- FDA issues warning letters to Baxter and Olympus over GMP and QSR violationsThe U.S. Food and Drug Administration sent formal warning letters to Baxter International and Olympus Medical Systems. The letters allege that both companies failed to meet required good manufactu…
- AbbVie’s lutikizumab meets primary endpoint in Phase 3 hidradenitis trial but falls short of market expectationsAbbVie announced that its experimental drug lutikizumab achieved its primary goal in a Phase 3 study of hidradenitis suppurativa, a chronic inflammatory skin disease. The Intrepid trial enrolled a…